Newsletter sign-up

Transatlantic Diabetic Lower Extremity Symposium, Santorini, Greece
Thursday, 18 October 2018

We look forward to attending this conference, where we have a podium and poster presentation.

Symposium of Advanced Wound Care, Las Vegas
Friday, 2 November 2018

Please come and visit us at our booth to learn more about 3C Patch. There will also be podium and poster presentations about our technology at this conference.

Innovations In Wound Healing, Key Largo
Saturday, 8 December 2018

We look forward to attending this conference, where there will be podium and poster presentations regarding 3C Patch.

< Back to overview

New help on the way for people with diabetic foot ulcers

by Rasmus Lundquist

A major international randomized controlled trial (RCT) has just been published in the internationally recognized journal The Lancet Diabetes & Endocrinology and documents the effect of a new treatment, LeucoPatch®, which offers significant enhancement of healing of hard-to-heal foot ulcers.

The Danish medtech company Reapplix has paved the way for commercialization of its new technology, LeucoPatch®, which may save patients with hard-to-heal foot ulcers from amputations and the related risk of premature death

A newly published RCT shows that LeucoPatch® has a significantly better effect on chronic diabetic foot ulcers than standard care. The study, which was the first of its kind, was published this week in The Lancet Diabetes & Endocrinology

In Denmark alone, 22,000 people suffer from diabetic foot ulcers, resulting in approximately 1,000 amputations each year, and a total estimated health economic cost of 5 billion DKK

The marketing of LeucoPatch® technology has begun in Denmark. Reapplix holds the patents and the global rights to LeucoPatch®

Reapplix is now primed to market its novel product LeucoPatch®. This provides new hope to people globally who suffer from very hard to heal diabetic foot ulcers. Paving the way for this milestone are the results of an international five-year research project showing that LeucoPatch® has a significantly better effect on chronic diabetic foot ulcers than traditional treatment. The results have just been published in the internationally recognized journal The Lancet Diabetes & Endocrinology and are to be presented at the Diabetic Foot Study Group Conference 28-30 September 2018, and at the annual meeting of the European Association for the Study of Diabetes (EASD), 1-5 October 2018, both in Berlin.

Press release 21 September 2018

Top